Item 8.01 Other Events.

On April 12, 2021, VBI Vaccines Inc. (the "Company") issued a press release announcing that data and next steps from the high-dose cohort of its Phase 1b/2a clinical study of VBI-2601 (BRII-179), the Company's hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients. VBI-2601 (BRII-179) is being developed in collaboration with Brii Biosciences as part of a potential functional cure for chronic hepatitis B virus infection. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated April 12, 2021
104           Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses